1. NovioTech BV
Technology to the Market
From Glucose Sensor to Hydrogel
Hans Hanssen (CTO)
Presented 30 June 2011 to Valorisation UMC Radboud
2. About NovioTech BV
• Shareholders:
• Tweehuysen Holding BV
• Hanssen Investment and Consultancy BV
• Prof. Jan van Hest
• Prof. Alan Rowan
• Scientific Advisor: Prof Roeland Nolte
www.noviotech.com
3. About the Speaker: Hans Hanssen
• Former CEO of MCTEC
• Co-Founder of DSE BV, Eyetube BV, MCTEC BV,
NovioTech BV
• Business Advisor to EPFlex GmBH, Nano4Imaging
BV, Encapson BV
4. Outline of the Talk
• NovioSense – Glucose Sensor Technology
• NovioHelix – Novel Thermogel Technology
6. Diabetes
• At this moment World Health Organization estimates 5-7% of the worldpopulation
has diabetes.
• This will increase within the next 20 years to 300 million.
• Diabetes can lead to:
– Heart disease and stroke
– High blood pressure
– Blindness
– Kidney disease
– Nervous system disease (Neuropathy)
– Amputation
11. 9.00E-07
y = 5.36E-07x + 2.10E-07
8.00E-07 R2 = 9.96E-01
7.00E-07
6.00E-07
Current (A)
5.00E-07
4.00E-07
3.00E-07
2.00E-07
1.00E-07
0.00E+00
0 0.5 1
Glucose conc. (mM)
The resulting current is linear within
the concentration regime of glucose
levels in tear fluid
14. Project Status
Patent Pending: NovioTech Assignee
Contact with Major Players in the Glucose Management Industry
Raised €1.1M of Inter Regional Funding
Goal is Functional Prototypes in 12 Months From Now
16. Warm
Cool
Gel formation at up to 99.98% water
Programmable transition temperatures
Optically Transparent
Biocompatible
Forms Nano-Pores (100-250nm)
Stiffness from (10 - 1000Pa)
23. Project Status
Identified Dedicated Project Manager
Patent Pending: NovioTech has Exclusive License
Promising New Thermo Responsive Nano Material
Identify Most Promising Market Areas
Early Prototype NanoWipe
Proof of Principle BioMedical Applications Underway